How to Get Tresiba in Missouri: Prescriptions, Telehealth, and Pharmacy Access

What Is Tresiba and Why Missouri Patients Are Seeking It

Insulin degludec is a long-acting basal insulin analog with a half-life exceeding 25 hours, producing a flat, stable action profile that can last up to 42 hours in some patients. It differs from glargine U-100 and detemir primarily in its ultra-long duration and its flexibility around injection timing. Missouri prescribers and patients are showing growing interest in it because the DEVOTE cardiovascular outcomes trial demonstrated a 40% reduction in severe hypoglycemia compared to insulin glargine U-100, a finding that changes the calculus for patients with hypoglycemia unawareness or high cardiovascular risk. [1]

The FDA approved Tresiba in September 2015 for adults with type 1 and type 2 diabetes, and expanded the label to include pediatric patients (age 1 and older) with type 1 diabetes in 2019. [2] The drug is available as Tresiba FlexTouch pens in U-100 (100 units/mL, 3 mL) and U-200 (200 units/mL, 3 mL) concentrations. Dose errors between concentrations are a known safety concern, so the FDA label specifies that U-200 must never be used in an insulin pump or measured with a U-100 syringe. [2]

Missouri has approximately 394,000 adults living with diagnosed diabetes according to CDC state surveillance data, and a meaningful proportion of those patients use basal insulin as part of their regimen. [3] For many, switching to insulin degludec is a clinical decision driven by hypoglycemia burden, injection-timing convenience, or HbA1c that remains above target on their current basal.

Step One: Getting a Prescription in Missouri

A valid Missouri prescription for Tresiba requires a licensed prescriber with Missouri DEA registration (or a telehealth provider holding an active Missouri license). Missouri does not restrict basal insulin prescribing to endocrinologists. A primary care physician, nurse practitioner with full prescriptive authority, or physician assistant working under a supervising physician can all write this prescription. [4]

The prescriber will typically review your most recent HbA1c, a fasting plasma glucose log or CGM data, current insulin doses if you are already on basal therapy, kidney function (eGFR), and any history of hypoglycemic episodes. The FDA label recommends a starting dose of 10 units once daily for insulin-naive type 2 patients, titrated in increments of 2 units every 3 to 4 days until fasting self-monitored blood glucose is consistently between 80 and 130 mg/dL. [2] Patients converting from another basal insulin should begin at a unit-for-unit substitution and then titrate.

Missouri law (RSMo § 334.104) authorizes collaborative practice agreements between physicians and advanced practice registered nurses, which means NPs at telehealth platforms can prescribe Tresiba within a properly structured collaborative framework even for new patients. [4] Physician assistants in Missouri must have a written supervision agreement on file per RSMo § 334.735. [5]

Fasting glucose logs covering at least 2 weeks, or a 14-day CGM ambulatory glucose profile, provide the most useful baseline data before starting titration. The American Diabetes Association 2024 Standards of Care recommend confirming renal function before initiating or intensifying any insulin regimen, because eGFR <30 mL/min/1.73m² warrants dose reduction planning. [6]

Telehealth Prescribing for Tresiba in Missouri

Missouri telehealth providers can legally prescribe Tresiba to new patients after a synchronous audio-video visit that includes a documented medical evaluation. The Missouri Telehealth Act and subsequent guidance from the Missouri Board of Healing Arts confirm that a prescriber-patient relationship can be established via telemedicine without a prior in-person encounter, provided the standard of care is met. [4]

Telehealth is a practical path for Missouri residents in rural counties. Many rural Missouri counties have fewer than 5 endocrinologists per 100,000 population, creating substantial wait times for specialist care. A telehealth consultation with a licensed Missouri prescriber typically takes 20 to 40 minutes and can result in a same-day electronic prescription sent to any Missouri-licensed pharmacy or mail-order pharmacy.

Platforms operating in Missouri must hold active Missouri prescriber licenses and must comply with Missouri Board of Pharmacy rules for electronic prescribing of non-controlled substances. Insulin degludec is not a controlled substance under Missouri or federal schedules, so it can be prescribed electronically without the additional DEA requirements that apply to Schedule II drugs. [5]

After the visit, the prescriber sends an electronic prescription to your chosen pharmacy. Most Missouri retail pharmacy chains (Walgreens, CVS, Schnucks, Price Cutter, and independent pharmacies) can fill Tresiba FlexTouch pens, though U-200 stock varies and may require a 24-to-48-hour special order. Mail-order pharmacies typically ship with 2-day cold-pack delivery to Missouri ZIP codes.

Prior Authorization in Missouri: What to Expect

Most Missouri commercial insurance plans and managed-care Medicaid plans require prior authorization (PA) for Tresiba before covering it. The PA process is arguably the biggest friction point in accessing this medication. Here is what that process typically involves.

Your prescriber submits a PA request documenting the clinical rationale, usually including your most recent HbA1c (commonly required to be above 7.0% or above 8.0% depending on the plan), evidence of a trial of at least one preferred formulary basal insulin (most often glargine U-100 or glargine U-300), and documentation of the reason for switching. Acceptable clinical reasons typically include recurrent severe hypoglycemia, hypoglycemia unawareness, or HbA1c above target despite optimized glargine dosing. [6]

The Centers for Medicare and Medicaid Services defines prior authorization as a utilization management tool that "requires approval before a prescription drug is dispensed to ensure coverage criteria are met." Missouri's Medicaid managed care organizations (MO HealthNet) apply PA criteria that align with MO HealthNet's Preferred Drug List, updated quarterly. [7] As of the 2025 MO HealthNet PDL, insulin degludec is non-preferred for type 2 diabetes and not covered for that indication under standard Medicaid, though type 1 diabetes coverage is available with PA. [7]

For commercial plans, the timeline from PA submission to decision is typically 3 to 15 business days for a standard review or 24 to 72 hours for an urgent review. If the PA is denied, your prescriber can request a peer-to-peer review, and you have the right to a formal appeal. The DEVOTE trial data, which showed a statistically significant 40% reduction in confirmed or severe hypoglycemic episodes (rate ratio 0.60 to 95% CI 0.54 to 0.67, P<0.001) with degludec vs. glargine, is useful clinical evidence to cite in an appeal. [1]

Missouri law under RSMo § 376.1367 requires insurers to provide a written denial explanation and the right to external review by an independent review organization. [8] Keep copies of all PA correspondence.

Missouri Pharmacy Options: Retail, Mail-Order, and 503A Compounding

Retail pharmacies. Tresiba FlexTouch U-100 is stocked at most large-chain Missouri pharmacies. Call ahead for U-200, as availability is inconsistent outside of major metro areas (St. Louis, Kansas City, Springfield, Columbia). GoodRx and NovoCare manufacturer coupons can reduce out-of-pocket costs at retail. The NovoCare Patient Assistance Program provides Tresiba at no cost to uninsured or underinsured patients with household income at or below 400% of the federal poverty level. [9]

Mail-order pharmacies. Express Scripts, CVS Caremark, Optum Rx, and Mark Cuban's Cost Plus Drugs all ship to Missouri. Insulin degludec must be shipped refrigerated (36°F to 46°F / 2°C to 8°C). Once opened, pens can be kept at room temperature (below 86°F / 30°C) for up to 56 days, which the FDA label specifies explicitly. [2] Missouri residents in ZIP codes with extreme summer temperatures should confirm that pharmacy cold-chain practices meet these storage standards.

503A compounding pharmacies. Missouri-licensed 503A pharmacies can compound insulin degludec for individual patients when a prescriber documents a specific clinical need that cannot be met by the commercially available product (for example, a patient requiring a non-standard concentration for a specialized dosing device). Section 503A of the Federal Food, Drug, and Cosmetic Act governs this pathway, and the pharmacy must compound for a specific patient pursuant to a valid prescription. [10] The FDA does not approve compounded drugs, and the quality, potency, and sterility of compounded insulin depend on the pharmacy's compliance with USP <797> sterile compounding standards. [10] Ask any Missouri 503A pharmacy whether they hold a current Missouri Board of Pharmacy compounding license and whether their sterile preparations are tested by an independent ISO-accredited lab.

Transferring an Existing Tresiba Prescription to Missouri

Patients relocating to Missouri, or those who have been prescribed Tresiba in another state, can transfer their prescription to any Missouri-licensed pharmacy. Non-controlled substance prescriptions may be transferred between pharmacies under Missouri Board of Pharmacy Rule 20 CSR 2220-2.018. [5] The receiving pharmacy contacts the original pharmacy to complete the transfer; the patient does not need to obtain a new prescription as long as authorized refills remain.

If the original prescription has no refills remaining, a Missouri-licensed prescriber must write a new prescription. A telehealth visit is sufficient for this purpose, provided the prescriber documents a clinical review adequate to confirm that the current dose and indication remain appropriate. Bring records of your most recent HbA1c, any CGM reports, and your current injection dose to the telehealth visit to expedite that review.

Patients moving from a state with different Medicaid programs should be aware that Missouri Medicaid (MO HealthNet) does not automatically honor prior authorization approvals granted by another state's Medicaid program. A new PA will be required.

Clinical Evidence Supporting Insulin Degludec

The DEVOTE trial (N=7,637) is the foundational outcomes study for insulin degludec. Published in the New England Journal of Medicine in 2017, DEVOTE was a double-blind, treat-to-target trial comparing degludec U-100 to glargine U-100 in adults with type 2 diabetes at high cardiovascular risk over a median 2-year follow-up. The primary cardiovascular endpoint (3-point MACE) was non-inferior for degludec vs. glargine (hazard ratio 0.91 to 95% CI 0.78 to 1.06). The pre-specified secondary endpoint showed degludec produced 40% fewer severe hypoglycemic episodes (rate ratio 0.60 to 95% CI 0.54 to 0.67, P<0.001). [1] The nocturnal severe hypoglycemia rate was reduced by 53% (rate ratio 0.47 to 95% CI 0.38 to 0.58, P<0.001). [1]

The BEGIN trials series, a set of Phase 3 randomized controlled trials conducted pre-approval, compared insulin degludec to glargine U-100 across type 1 and type 2 diabetes populations. BEGIN Once Long in type 2 diabetes (N=1,030) showed similar HbA1c reduction with degludec vs. glargine (-1.06% vs. -1.19%, respectively) over 52 weeks, with a 17% lower rate of confirmed hypoglycemic episodes with degludec (rate ratio 0.83 to 95% CI 0.69 to 1.00). [11] BEGIN Basal-Bolus Type 1 (N=629) demonstrated comparable HbA1c reduction with a lower rate of nocturnal confirmed hypoglycemia with degludec (rate ratio 0.75 to 95% CI 0.59 to 0.96, P=0.021). [12]

The American Diabetes Association's 2024 Standards of Medical Care in Diabetes state: "For patients with type 1 or type 2 diabetes at high risk of hypoglycemia, insulin analogs with a lower hypoglycemia risk profile (such as insulin degludec or glargine U-300) are preferred over NPH or glargine U-100." [6] This language directly supports prior authorization appeals and telehealth prescribing decisions in Missouri.

The Endocrine Society's clinical practice guideline on diabetes pharmacotherapy notes that ultra-long-acting basal insulins provide more predictable pharmacokinetics than intermediate-acting insulins, making them preferable for patients with erratic schedules or those experiencing dawn phenomenon. [13]

For patients with cardiovascular disease, the DEVOTE cardiovascular safety data gave physicians the confirmatory evidence needed to prescribe degludec without concern about worsening cardiac outcomes, a standard now required by the FDA for all new diabetes drugs following the 2008 guidance on cardiovascular outcomes trials. [14]

Missouri-Specific Cost and Coverage Decision Framework

Commercial insurance patients in Missouri should run through this sequence before paying out of pocket:

First, confirm your plan's formulary tier for insulin degludec. Tier 3 or 4 placement is common, meaning PA is required and cost-sharing is higher. Second, submit PA with DEVOTE hypoglycemia data and any documented hypoglycemic events from your glucose logs. Third, if denied, request a peer-to-peer review: prescriber-to-medical-director calls resolve many denials when the clinical rationale is presented with trial data. Fourth, if the appeal fails, check eligibility for the Novo Nordisk Patient Assistance Program and the NovoCare $99/month cap program for commercially insured patients who qualify. [9] Fifth, consider 90-day supply dispensing at mail-order to reduce per-unit cost.

Uninsured Missouri patients without prescription coverage pay approximately $280 to $430 per FlexTouch pen at retail without discount cards. GoodRx typically brings that price to $180 to $260 per pen at Missouri pharmacies, though prices vary by city and chain. Cost Plus Drugs lists insulin degludec at a significantly lower margin, though inventory availability should be confirmed before relying on that source. [15]

Labs and Monitoring Before and During Tresiba Therapy

Before starting insulin degludec, your Missouri prescriber will likely order or review the following: HbA1c (to confirm current glycemic status and document baseline), fasting plasma glucose or 14-day CGM report, comprehensive metabolic panel including serum creatinine and calculated eGFR, and weight. Patients with eGFR <30 mL/min/1.73m² may need more conservative dose titration because glucose counter-regulatory responses can be blunted in advanced chronic kidney disease. [6]

After starting Tresiba, fasting self-monitored blood glucose should be checked daily during the titration period, targeting 80 to 130 mg/dL per ADA 2024 targets. [6] A follow-up HbA1c at 3 months allows assessment of whether basal insulin alone is achieving glycemic goals or whether prandial insulin or a GLP-1 receptor agonist needs to be added. The FDA label specifies that dose adjustments should be based on metabolic needs, blood glucose monitoring results, and glycemic goals, and that changes should not be made more frequently than every 3 to 4 days during titration. [2]

CGM data, when available, provides a more complete picture than fingerstick HbA1c alone. The ADA 2024 Standards recommend that time-in-range (70 to 180 mg/dL) exceed 70% for most adults with type 1 or type 2 diabetes, with time below range <70 mg/dL kept below 4%. [6] Missouri telehealth prescribers can review uploaded CGM data (Dexterity, Libre, or Medtronic) remotely during follow-up visits, making ongoing Tresiba titration entirely compatible with telehealth-only care.